𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Abnormal properties of skin fibroblasts from patients with breast cancer

✍ Scribed by B. Azzarone; M. Mareel; C. Billard; P. Scemama; C. Chaponnier; A. Macieira-Coelho


Publisher
John Wiley and Sons
Year
1984
Tongue
French
Weight
623 KB
Volume
33
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The growth properties of fibroblasts from the thoracic skin of patients with mammary cancers were compared to those of fibroblastic cultures from patients with benign lesions or having undergone surgery for non‐neoplastic diseases. As expected, an inverse correlation was found between the doubling potential of fibroblasts in vitro and the donor's age for cells from patients with benign lesions; however no correlation, was found with cultures from cancer patients. Moreover, the latter group responded in an abnormal way to three biological parameters: anchorage dependence, colony formation on monolayers of normal human epithelial cells and saturation densities in overcrowded culture conditions. Skin fibroblasts from one patient with a benign lesion, whose mother had developed a breast cancer, displayed all the abnormal growth properties. Periodic controls of this patient resulted in the early detection of a carcinoma 3 years after the first operation for a benign microcystic lesion. Finally, we found that multiple subcultivations in overcrowded culture conditions cause the selection of a fibroblastic cell subset with greater growth potential which, in the cell strain tested, could invade foreigh tissus in vitro.


πŸ“œ SIMILAR VOLUMES


Abnormal arylsulphatase activities of fi
✍ Furusho, K. ;Vetrella, M. ;Latta, E. πŸ“‚ Article πŸ“… 1971 πŸ› Springer-Verlag βš– 454 KB

The activity of arylsulphatases A and B was studied in cultured fibroblasts of 2 patients with Hurler's syndrome, 2 patients with Hunter's syndrome and 2 patients with eystinosis. The activity of arylsulphatase A was found to be lower in fibroblasts in patients with Hurler's syndrome than in the co

Lack of response in nine patients with b
✍ U. Bruntsch; G. Groos; F. -J. Tigges; P. H. Hofschneider; W. M. Gallmeier πŸ“‚ Article πŸ“… 1984 πŸ› Springer 🌐 English βš– 380 KB

Nine patients with metastatic breast cancer were treated with a minimum of 6 x 106 U/day of t3-interferon (IFN-t3) for at least 6 weeks. In patients whose disease did not progress during this period treatment was continued to a maximum of 13 weeks, while in other patients doses were escalated. With